Dr. Charles Baker -- Pharma Payment Report

Payment Summary

• Total Payments Received: $15,735.99
• Number of Transactions: 1
• Transparency Score: 50/100

Payment Breakdown

• speaking: $0.00
• travel: $0.00
• ownership: $0.00
• consulting: $15,735.99
• research: $0.00
• meals: $0.00

AI Analysis

Dr. Charles Baker, an ophthalmologist in City, WA, has a pharmaceutical payment profile characterized by a single, significant payment. With a total of $15,735.99 from pharmaceutical companies, this amount is notably higher than the typical annual payments received by many physicians, especially when considering it stems from just one transaction. The data indicates that Johnson & Johnson is the sole pharmaceutical company with a recorded payment to Dr. Baker, totaling the entire $15,735.99. This payment, dated August 8, 2024, was for consulting services. The concentration of the entire payment volume from a single company and for a specific service like consulting warrants a closer look, though it doesn't automatically signal impropriety. In the field of ophthalmology, payment volumes can vary widely. While some ophthalmologists engage in extensive research, speaking engagements, or consulting that can lead to substantial payments, others receive minimal or no direct payments. A single, large consulting fee, as seen here, is less common than a pattern of smaller, more frequent payments for various activities like meals, speaker fees, or advisory board participation. This singular payment, while substantial in isolation, does not establish a pattern of routine engagement with pharmaceutical companies. For patients, understanding these relationships is crucial. Pharmaceutical companies invest in physicians to educate them about new drugs, devices, and treatment protocols. Consulting fees, in particular, are intended to compensate physicians for their expertise and insights, often related to product development or market strategy. However, such relationships can create potential conflicts of interest, as they may subtly influence a doctor's prescribing habits or treatment recommendations towards the products of the paying company. Patients should be aware that while these payments are publicly disclosed, they are a piece of a larger puzzle in evaluating their physician's practice. What patients should know is that transparency in healthcare payments is designed to empower them with information. While a single large payment for consulting might be legitimate compensation for valuable expertise, it's also an opportunity for patients to engage in a conversation with their doctor about treatment options and potential biases. It is important to consider this payment in the context of the doctor's overall practice, patient reviews, and established clinical guidelines when making healthcare decisions.

Patient Guidance

When considering your doctor's pharmaceutical payment history, it's important to view it as one factor among many. A single large payment for consulting, as seen with Dr. Baker, could represent legitimate compensation for specialized expertise. However, it's always wise to maintain open communication. At your next appointment, consider asking your doctor about the treatments they recommend and if there are alternative options available, especially if a particular drug or device is mentioned. Inquire about the rationale behind their choices and if their recommendations align with established clinical guidelines. Red flags might include a pattern of frequent, small payments (like meals or speaker fees) alongside a tendency to prescribe the drugs of the companies making those payments, especially if those drugs are not clearly superior to alternatives. Conversely, a doctor who is transparent about their relationships, discusses various treatment options, and bases recommendations on evidence-based medicine, even if they have industry ties, is generally a positive sign. Normal professional activity often involves consulting, speaking, or research, especially for physicians involved in innovation or education. What might warrant closer attention is a lack of transparency, a consistent preference for a specific company's products without clear clinical justification, or a history of significant payments that seem disproportionate to the physician's stated activities. Ultimately, evaluate your doctor's overall care, communication style, and the outcomes you experience, using payment data as a tool for informed discussion, not as the sole determinant of trust.

Peer Comparison

The average annual pharmaceutical payments for ophthalmologists can range significantly, often from a few hundred dollars to tens of thousands, depending on their level of industry engagement. A single payment of $15,735.99 for consulting, while substantial, is not necessarily indicative of widespread industry influence if it represents a one-off engagement. Compared to ophthalmologists who receive numerous smaller payments for meals, speaking, or research, Dr. Baker's profile shows a singular, large transaction. This places him outside the typical pattern of frequent, smaller interactions but doesn't inherently suggest excessive reliance on industry funding without further data.

Recent Payments

Frequently Asked Questions

Is Dr. Charles Baker taking too much pharma money?

Dr. Baker received a single payment of $15,735.99 for consulting from Johnson & Johnson. While this is a substantial amount for a single transaction, it is difficult to definitively label it as 'too much' without a broader context of his overall practice and comparison to peers. Many ophthalmologists receive no payments, while others engage in significant consulting or research that can lead to higher figures. This single payment doesn't establish a pattern of routine financial ties, but it does represent a significant financial interaction with one company.

What pharma companies pay Dr. Charles Baker?

Based on the available data, Dr. Charles Baker received payments exclusively from Johnson & Johnson. The total amount paid by Johnson & Johnson to Dr. Baker is $15,735.99.

Should I switch doctors because of pharma payments?

Switching doctors solely based on pharmaceutical payments is a significant decision. A single large payment, like Dr. Baker's consulting fee, might be for legitimate expertise. Consider if your doctor is transparent, discusses all treatment options, and bases recommendations on evidence. If you have concerns about potential bias, discuss them openly with your doctor. If trust is eroded or you feel your concerns are not addressed, seeking a second opinion or a new physician might be appropriate, but this decision should be based on a holistic view of your care.

What kinds of payments does this doctor receive?

Dr. Charles Baker received one payment totaling $15,735.99. This payment was categorized as 'consulting' and was made by Johnson & Johnson in 2024.

How do these payments compare to other Ophthalmology?

Dr. Baker's single payment of $15,735.99 for consulting is a notable amount for one transaction. While many ophthalmologists receive no payments, others engage in more frequent, smaller payments for various services. This singular large payment is less typical than a pattern of smaller, recurring payments often seen in the specialty, placing his profile outside the most common engagement models.

Do pharma payments affect prescribing quality?

Research suggests that even small payments from pharmaceutical companies can influence physician prescribing habits, often subtly. While payments for consulting, research, or speaking can be legitimate compensation for expertise, they can also create a bias towards the paying company's products. Evidence indicates that physicians receiving industry payments may be more likely to prescribe newer, more expensive drugs from those companies, even when equally effective, less costly alternatives exist. Transparency aims to help patients assess this potential influence.

How can I verify this payment data?

You can verify this payment data directly through the Centers for Medicare & Medicaid Services (CMS) Open Payments database. Visit the official CMS Open Payments website and use the search function to look up physicians by name and National Provider Identifier (NPI). The database provides detailed records of payments made by pharmaceutical and medical device companies to physicians and teaching hospitals, allowing you to review the specific amounts, dates, companies, and purposes of these transactions.